

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Alzheimer's disease (AD)	ATP-binding cassette transporter-1 (ABCA1)	Studies in mice suggest that increasing ABCA1 levels could be a strategy for treating AD. In the CNS, ABCA1 transfers lipids to apolipoprotein E (apoE), which has been associated with increased susceptibility to late-onset AD. Brain-specific overexpression of ABCA1 in an AD mouse model increased lipid transfer to apoE and led to decreased amyloid- β deposition. Next steps include determining how increased transfer of lipids to apoE in the brain influences the ability of apoE-containing lipoprotein particles to interact with amyloid- β .	Not applicable	Wahrle, S. <i>et al. J. Clin. Invest.</i> ; published online Jan. 17, 2008; doi: 10.1172/JCI33622 Contact: David M. Holtzman, Washington University School of Medicine, St. Louis, Mo. e-mail: holtzman@neuro.wustl.edu